Zetia vs. Leqvio
See how Zetia and Leqvio compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Zetia is a once-daily pill that blocks cholesterol absorption in the gut, while Leqvio is an injection that silences PCSK9 production in the liver just twice a year after starting doses.
Leqvio generally produces larger LDL-C reductions than Zetia, but it requires a clinician-administered injection instead of a pill you take at home.
Zetia has been available as an affordable generic since the mid-2010s, while Leqvio is a newer injectable therapy usually reserved for patients who need additional LDL lowering.
Zetia vs. Leqvio Drug Summary
Zetia
Zetia (ezetimibe) is a cholesterol absorption inhibitor used to lower LDL cholesterol in adults and certain adolescents with high cholesterol. It's taken as a once-daily oral tablet, either alone or combined with a statin or fenofibrate.
Leqvio
Leqvio (inclisiran) is a PCSK9 synthesis inhibitor that uses siRNA technology to lower LDL cholesterol in adults and adolescents with hypercholesterolemia. It's given as a subcutaneous injection on Day 1 and Day 90, then just twice a year for maintenance.
Zetia vs. Leqvio Side Effects
Zetia
Leqvio
Zetia vs. Leqvio Dosage
Zetia
Leqvio
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 10 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 284 mg injection | Day 1 |
| Maximum dose | 284 mg injection | Same as starting |
| Dose changes | None | Fixed dose |
Zetia
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg once daily | At the start |
| Maximum dose | 10 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Leqvio
| STAGE | DOSE | WHEN |
| Starting dose | 284 mg injection | Day 1 |
| Maximum dose | 284 mg injection | Same as starting |
| Dose changes | None | Fixed dose |
Zetia vs. Leqvio Indications
Zetia
Zetia is FDA-approved to lower LDL cholesterol as an add-on to diet, either alone or with a statin, in adults with primary hyperlipidemia. It's also approved for certain inherited high-cholesterol conditions, including familial hypercholesterolemia starting at age 10.
Lowers LDL-C in adults with primary hyperlipidemia, alone or with a statin
Used with a statin for heterozygous familial hypercholesterolemia (age 10+)
Combined with fenofibrate for mixed hyperlipidemia
Combined with a statin for homozygous familial hypercholesterolemia (age 10+)
Leqvio
Leqvio is FDA-approved to lower LDL cholesterol as an add-on to diet and exercise in adults with hypercholesterolemia. It's also approved for heterozygous and homozygous familial hypercholesterolemia in patients aged 12 and older.
Lowers LDL-C in adults with hypercholesterolemia
Used for heterozygous familial hypercholesterolemia (age 12+)
Approved for pediatric homozygous familial hypercholesterolemia (age 12+)
Not approved for adults with homozygous familial hypercholesterolemia
Zetia vs. Leqvio Pros and Cons
Zetia
Zetia works by blocking cholesterol absorption in the gut, giving it a mechanism distinct from statins and PCSK9 therapies. It's inexpensive as a generic and easy to take, though its LDL-lowering effect is more modest than newer injectable options.
Pros
Oral pill, no injections needed
Available generically and widely covered by insurance
Long track record, on the market since 2002
Can be combined with a statin or fenofibrate for added LDL lowering
Cons
Must be taken every day to stay effective
Produces smaller LDL reductions than PCSK9-targeted therapies
Requires liver enzyme monitoring when combined with a statin
Not approved as monotherapy for homozygous familial hypercholesterolemia
Leqvio
Leqvio blocks PCSK9 production in the liver using siRNA technology, delivering strong LDL reductions with just two injections a year after the starting doses. It must be given by a healthcare provider and has a shorter track record than oral options like Zetia.
Pros
Only two maintenance injections per year after starting doses
Produces larger average LDL-C reductions than ezetimibe
Newer siRNA mechanism, silences PCSK9 production in the liver
No daily pill to remember
Cons
Must be given by a healthcare provider via injection
Approved more recently (2021), with less long-term real-world data
Injection site reactions are common
Not approved for adults with homozygous familial hypercholesterolemia
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.